DiaMedica Therapeutics doses first patient in Phase 2 DM199 trial

DiaMedica Therapeutics (DMAC) “announced that the first patient has been dosed in DiaMedica’s investigator-sponsored Phase 2 trial of DM199 for the treatment of preeclampsia. DiaMedica anticipates top line data for Part 1A in the first half of 2025 which is expected to demonstrate initial proof-of-concept including whether DM199 is safe and lowers blood pressure. Additionally, for patients with early onset PE, DiaMedica will be looking for improvements in uterine artery dilation, indicating that DM199 therapy is potentially disease modifying in these patients.”